UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 10, 2021
RESPIRERX PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Delaware | | 1-16467 | | 33-0303583 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S Employer Identification No.) |
126 Valley Road, Suite C Glen Rock, New Jersey | | 07452 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (201) 444-4947
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
N/A | | N/A | | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
RespireRx Pharmaceuticals Inc. (the “Company”) announced today, that its Chief Financial Officer, Jeff Margolis, will be presenting at the Life Sciences Virtual Investor Conference (“LSVIC”) on December 16, 2021 at 10:00 am EST. A copy of the press release describing the conference and the Company’s participation is attached as Exhibit 99.1. In addition, the presentation materials in the form of the slide deck to be presented is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
In the same press release that is Exhibit 99.1, RespireRx announced that the Company’s video presentation for the Biotech Showcase™ was made available by the Biotech Showcase™ on Friday, December 10, 2021 to registered participants. The slide deck, both in video and pdf format (without video), will be available on the Company’s website at www.respirerx.com and the pdf format (without video) is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.
The press release and the slide decks that are Exhibits 99.1, 99.2 and 99.3 include certain forward-looking information.
The information in this Item 7.01 and the documents attached as Exhibit 99.1, 99.2 and 99.3 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 14, 2021 | RESPIRERX PHARMACEUTICALS INC. |
| (Registrant) |
| | |
| By: | /s/ Jeff E. Margolis |
| | Jeff E. Margolis |
| | SVP, CFO, Secretary and Treasurer |